MapLight Therapeutics, Inc.
NASDAQ:MPLTBiotechnology
+$0.39 today
- Market cap
- $283.41M
- Beta
- 2.65
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$4.41
Volume 0.42M
Average 0.73M
MPLT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
MapLight Therapeutics, Inc.NASDAQ: MPLT
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation outflow grows to $0
Q1 FY2026 stock-based compensation was $0, compared with $0 a year earlier. Trailing-twelve-month stock-based compensation was $125K.
Context
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly stock-based compensation holds near $0 or moves back toward the trailing-twelve-month quarterly average of $31.25K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
Stock-Based Compensation vs competitors
How MPLT compares with its peers on the latest reported figures
- MPLT's LTM Mar 2026 stock-based compensation of $125K is the smallest of the 11 companies compared; the peer median is $11.61M.
- Its year-over-year change of -78.0% is the lowest of 9, against a peer median of -6.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $10.98B | — | +586.2% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $38.96M | +117.2% | +13.6% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $27.96M | -33.3% | +53.3% | — |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $21.78M | +70.4% | +213.9% | 108.9% |
| LTM Mar 2026 | $12.62M | -20.6% | +43.3% | 10.3% | |
| LTM Dec 2025 | $10.6M | +15.1% | -14.3% | — | |
| LTM Mar 2026 | $7.02M | -5.4% | +66.3% | — | |
| LTM Mar 2026 | $2.41M | -6.9% | -9.8% | 33.9% | |
| LTM Mar 2026 | $1.88M | -32.3% | — | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $1.37M | — | — | — |
| LTM Mar 2026 | $125K | -78.0% | — | — | |
| Peer median (excluding MPLT) | $11.61M | -6.1% | +48.3% | 33.9% | |
Competitors are the stored peer set for MPLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (30.02M) | (55.71M) | (77.58M) | (161.15M) |
| Depreciation & Amortization | 574K | 556K | 701K | 578K |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Change in Working Capital | 1.72M | 2.04M | (3.07M) | (12.84M) |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 |
| Other Working Capital | 1.72M | 2.04M | (3.07M) | (12.84M) |
| Other Non-Cash Items | 1.14M | 1.11M | 1.13M | 35.27M |
| Operating Cash Flow | (26.58M) | (52.01M) | (78.82M) | (138.14M) |
| Capital Expenditures | (746K) | (462K) | (770K) | (473K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (125.02M) | (408.23M) |
| Sales of Investments | 0 | 0 | 45M | 85.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (746K) | (462K) | (80.79M) | (323.21M) |
| Debt Repayment | 0 | 0 | 0 | 0 |
| Common Stock Issued | 33.17M | 104.57M | 120.25M | 474.84M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 33.18M | 104.57M | (2.19M) | (5.02M) |
| Financing Cash Flow | 33.17M | 104.57M | 118.06M | 469.82M |
| Effect of Forex Changes | 21.81M | 0 | 27K | 0 |
| Net Change in Cash | 27.67M | 52.1M | (41.52M) | 8.48M |
| Free Cash Flow | (27.32M) | (52.47M) | (79.59M) | (138.61M) |
MapLight Therapeutics, Inc.
NASDAQ:MPLT
Intrinsic Alpha fair value
Locked
Current Price
$6.65
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.